| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3288912 | Gastroenterología y Hepatología | 2007 | 5 Pages |
Abstract
Imatinib-induced hepatitis has a variable latency period, frequently of several months. Half of the patients develop anicteric hepatitis and the clinical course is generally benign. A distinguishing feature of this entity is a transitory increase in transaminase levels in patients diagnosed with hepatitis in the weeks after treatment withdrawal. Resumption of imatinib use provokes hepatitis recurrence, which can be avoided by simultaneous prednisone administration.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Francisco Fuster, Luis Medina, Rolando Vallansot, Miquel Granell, Miquel Bruguera,